Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials

Bio-Path Holdings, Inc. (OTCQB: BPTH), a clinical-stage biotechnology company, is making notable progress with its RNA interference (RNAi) therapeutics, leveraging its proprietary DNAbilize® platform. This technology, which enhances drug stability and cellular uptake while reducing toxicity, is at the forefront of developing treatments for acute myeloid leukemia (AML), solid tumors, and metabolic diseases like obesity and type 2 diabetes.

The company's lead candidate, prexigebersen (BP1001), targeting the Grb2 protein, is currently in Phase 2 trials for AML, with a modified version, BP1001-A, showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, aimed at the Bcl-2 protein, is being evaluated for blood cancers and solid tumors, with trials progressing to higher dose cohorts. Additionally, BP1003, a STAT3 inhibitor for pancreatic cancer, is in preclinical development, demonstrating successful tumor penetration in early trials.

Bio-Path's strategic relationships, including with The MD Anderson Cancer Center, and its strong intellectual property position underscore the potential of its DNAbilize® technology to revolutionize the delivery of antisense DNA therapeutics. Despite the need for additional funding to meet 2025 operational requirements, the company's undervaluation compared to peers and the nearing Phase 2 milestones for its lead drug candidate highlight its growth potential in the biotechnology sector.